PPARγ: Un récepteur nucléaire majeur de l’adipogenèse

Medecine/Sciences

Volumn 19, Issue 1, 2003, Pages 20-22

  Gervois, Philippe ^a,b   Fruchart, Jean Charles ^a,b  

^a INSTITUT PASTEUR DE LILLE   (France)

^b UNIV LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CELL RECEPTOR; CYTOKINE; TRANSCRIPTION FACTOR;

ADIPOCYTE; ADIPOSE TISSUE; ANIMAL; ARTICLE; CELL DIFFERENTIATION; CELL NUCLEUS; CELL STRAIN 3T3; CYTOLOGY; DRUG DESIGN; DRUG EFFECT; ENZYMOLOGY; GENETIC TRANSCRIPTION; GENETICS; HUMAN; INSULIN RESISTANCE; LIVER; METABOLISM; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOPHYSIOLOGY; PHYSIOLOGY; SKELETAL MUSCLE;

3T3 CELLS; ADIPOCYTES; ADIPOSE TISSUE; ANIMALS; CELL DIFFERENTIATION; CELL NUCLEUS; CYTOKINES; DIABETES MELLITUS, TYPE 2; DRUG DESIGN; HUMANS; INSULIN RESISTANCE; LIVER; MICE; MUSCLE, SKELETAL; OBESITY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 0042808675     PISSN: 07670974     EISSN: 19585381     Source Type: Journal    
DOI: 10.1051/medsci/200319120     Document Type: Article

References (14)

1. Gervois P, Torra IP, Fruchart JC, Staels B. Regulation of lipid and lipoprotein metabolism by PPAR activators. Clin Chem Lab Med 2000; 38: 3-11.
2. Nagy L, Tontonoz P, Alvarez JG, Chen H, Evans RM. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARy. Cell 1998; 93: 229-40.
3. Willson TM, Wahli W. Peroxisome proliferator-activated receptor agonists. Curr Opin Chem Biol 1997; 1: 235-41.
4. Rossi A, Kapahi P, Natoli G, et al. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase. Nature 2000; 403: 103-8.
5. Straus DS, Pascual G, Li M, et al. 15-deoxy-delta 12, 14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway. Proc Natl Acad Sci USA 2000; 97: 4844-9.
6. Kletzien RF, Clarke SD, Ulrich RG. Enhancement of adipocyte differentiation by an insulin-sensitizing agent. Mol Pharmacol 1992; 41: 393-8.
7. Brown KK, Henke BR, Blanchard SG, et al. A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat. Diabetes 1999; 48: 1415-24.
8. Rosen ED, Sarraf P, Troy AE, et al. PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell 1999; 4: 611-7.
9. Barak Y, Nelson MC, Ong ES, et al. PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol Cell 1999; 4: 585-95.
10. Ren D, Collingwood TN, Rebar EJ, Wolffe AP, Camp HS. PPARgamma knockdown by engineered transcription factors: exogenous PPARgamma2 but not PPARgamma1 reactivates adipogenesis. Genes Dev 2002; 16: 27-32.
11. Rosen ED, Hsu CH, Wang X, et al.C/EBPalpha induces adipogenesis through PPARgamma: a unified pathway. Genes Dev 2002; 16: 22-6.
12. Deeb SS, Fajas L, Nemoto M, et al. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998; 20: 284-7.
13. Beamer BA, Yen CJ, Andersen RE, et al. Association of the Pro12Ala variant in the peroxisome proliferator-activated receptor-gamma2 gene with obesity in two Caucasian populations. Diabetes 1998; 47: 1806-8.
14. Altshuler D, Hirschhorn JN, Klannemark M, et al. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 2000; 26: 76-80.